aiSLE DX Flare Risk Index
Commercial- Indications
- Systemic lupus erythematosus
Company intelligence / Profile preview
Progentec has launched commercial blood-based diagnostic tests to predict flares and measure disease activity in lupus patients. Early data support the ability of their proteomic/digital platforms to provide actionable information several weeks before clinical flare onset. Additional programs are advancing through proof-of-concept or pivotal studies targeting MS, NMO, Sjögren’s syndrome, and IBD.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Progentec Diagnostics.